Zealand Pharma advances a new generation of Type 2 Diabetes treatment
Zealand Pharma is developing a new treatment, ZP2929, for Type 2 Diabetes. ZP2929 has the potential to significantly decrease body weight and reduce the risk of Diabetes-related complications. ZP2929 is a dual Glucagon-GLP-1 agonist, a peptide drug which interacts with two receptor systems that play a role in metabolism and Type 2 Diabetes. Zealand Pharma's new drug has the promise of significantly lowering the weight of people with diabetes who are overweight or obese, thereby preventing related illnesses such as cardiovascular disease. The drug is now moving into pre-clinical development.
"We have been through a long and exciting research period. The result is a new dual Glucagon-GLP-1 agonist that both controls the blood glucose levels and reduces weight in obese diabetic models," says Dr. David H Solomon, CEO of Zealand Pharma.
The Type 2 Diabetes market is characterized by strong competition. ZP2929 potentially has to compete with another class of compounds, the GLP-1 agonists, having an effect on weight loss. ZP2929 has been compared to a marketed GLP-1 agonist in pharmacological studies and the results show that ZP2929 induces superior and sustained weight loss.
"We feel confident that our new dual Glucagon-GLP-1 agonist ZP2929, with its unique properties, will lead to a greater weight loss than its competitors," states Solomon.
Other news from the department research and development
